A Single-arm Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injections for the Treatment of Advanced Solid Tumors
Latest Information Update: 19 Feb 2025
At a glance
- Drugs GT-316 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors GRIT Biotechnology
- 07 Feb 2025 Planned number of patients changed from 30 to 36.
- 26 Oct 2023 New trial record